MGAT2 and Other metabolic disease: In the current study, we report a further investigation of the effects of MGAT2 inhibition on (a) fat‐induced gut peptide release and fat intake in normal mice and (b) metabolic disorders in HFD‐fed ob/ob mice—a model of severe obesity and type 2 diabetes mellitus—using another MGAT2 inhibitor, Compound B (CpdB).